Comparative Pharmacology
Head-to-head clinical analysis: HC HYDROCORTISONE versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC HYDROCORTISONE versus PENECORT.
HC (HYDROCORTISONE) vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokine production; and causes vasoconstriction and immunosuppression.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Hydrocortisone 100-500 mg IV/IM every 2-6 hours as needed for acute adrenal insufficiency or severe inflammation. Maintenance: 20-30 mg/day PO divided every 8-12 hours.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
1.5–2.5 hours (terminal half-life). In clinical context, the biological half-life (duration of HPA suppression) is longer (8–12 hours) due to tissue binding and active metabolites.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal: predominantly as conjugated metabolites and a small fraction of unchanged drug. Biliary/fecal: minor, <5%. Total renal clearance accounts for >95% of elimination.
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid